PRIMARY STUDY
Associations between Plasma Lipid Mediators and Chronic Daily Headache Outcomes in Patients Randomized to a Low Linoleic Acid Diet with or without Added Omega-3 Fatty Acids
Key Findings: 12-week oral linoleic acid (LA) lowering with or without increased n-3 PUFA intake resulted in increased free DHA-epoxides in the plasma of patients with chronic daily headaches and was associated with better headache control and physical and mental health improvements, as well as reduced headache interferences in daily activities and quality of life.
Type of Study: Clinical Trial
Study Sample Size: 67
Study Result: Positive
Research Location(s): United States
Year of Pub: 2023
Cannabinoids Studied: Omega-3, Omega-6, Diet
Phytocannabinoid Source: Not Applicable
DOSING DETAILS 
Study Dosing Objective: Effective Dose,
Established Protocol: Effective dose
Route of Administration: Oral (Ingestion)
Dosing Regimen: The L6 diet contained: LA (≤2.5 en%), AA (60 mg), ALA (0.6 en%), and EPA + DHA (125 mg) The H3-L6 diet contained: LA (≤2.5 en%), AA(150 mg), ALA (>1.5 en%), and EPA + DHA (>1000 mg)
Treatment Duration: 12 weeks
Clinical Relevance: 12-weeks of adding dietary LA led to better headache control and functional improvements in physical and mental health, as well as reduced headache interferences in daily activities in subjects with chronic daily headaches.
Citation: Shen Q, et al. Associations between Plasma Lipid Mediators and Chronic Daily Headache Outcomes in Patients Randomized to a Low Linoleic Acid Diet with or without Added Omega-3 Fatty Acids. Metabolites. 2023; 13:(unknown pages). doi: 10.3390/metabo13060690
Authors: Shen Q, Yang J, Zamora D, Horowitz M, Faurot KR, MacIntosh BA, Mann JD, Hammock BD, Ramsden CE, Taha AY
